Feds OK Epileptic Drivers for Interstate Semi-Trucks: Huh?
Published Date: 9/9/2026
Notice
Summary
FMCSA announces its decision to exempt 14 individuals from the requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) that interstate commercial motor vehicle (CMV) drivers have "no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV." The exemptions enable these individuals who have had one or more seizures and are taking anti- seizure medication to operate CMVs in interstate commerce.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
14 Drivers Granted Epilepsy Exemptions
FMCSA granted exemptions to 14 named individuals, allowing them to operate interstate commercial motor vehicles despite a history of seizures while taking anti-seizure medication. The exemptions became effective April 21, 2026 and run through April 21, 2028; the applicants had been seizure-free for between 4 and 22 years and on a stable treatment regimen for the last 2 years.
Ongoing Medical and Reporting Conditions
Drivers operating under these exemptions must remain seizure-free, keep a stable treatment, and report a seizure to FMCSA within 24 hours. They must also provide annual physician attestations and medical examinations, supply annual certified driving records, report crashes and certain citations within 7 days, carry a copy of the exemption while driving, and meet all commercial driver's license testing requirements.
Federal Exemption Preempts State Conflicts
While these exemptions are in effect (April 21, 2026 through April 21, 2028), no State may enforce a law or regulation that conflicts with the exemption for a person operating under it. This federal preemption protects the exempted drivers from state rules that would otherwise prevent interstate operation during the exemption period.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-08144, Administrative Rulemaking, Guidance, and Enforcement Procedures
The Department of Transportation is bringing back and improving its rules for making new policies, giving guidance, and enforcing laws. This affects anyone involved in transportation regulations, making the process clearer and more consistent. These changes kick in on May 27, 2026, aiming to save time and avoid confusion without adding extra costs.
2026-18312, Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders
FMCSA announces its decision to renew exemptions for five individuals from the requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) that interstate commercial motor vehicle (CMV) drivers have "no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV." The exemptions enable these individuals who have had one or more seizures and are taking anti-seizure medication to continue to operate CMVs in interstate commerce.
2026-18276, Agency Information Collection Activities; Renewal of an Approved Information Collection: Accident Recordkeeping Requirements
The Federal Motor Carrier Safety Administration is renewing its rules that require truck and bus companies to keep records of any accidents involving their vehicles. These companies don’t have to report accidents right away but must show the records if officials ask. The renewal keeps things running smoothly with no new costs, and comments on the plan are open until November 9, 2026.
2026-18270, Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders
The FMCSA is considering special permission for 21 drivers with epilepsy or seizure disorders to drive commercial trucks across state lines. These drivers take medication and want a chance to work despite current rules that usually say no. You can share your thoughts by October 9, 2026, and this could open new job opportunities without extra costs for the public.
2026-18308, Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders
FMCSA announces receipt of applications from 18 individuals for an exemption from the prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs) against persons with a clinical diagnosis of epilepsy or any other condition that is likely to cause a loss of consciousness or any loss of ability to control a commercial motor vehicle (CMV) to drive in interstate commerce. If granted, the exemptions would enable these individuals who have had one or more seizures and are taking anti-seizure medication to operate CMVs in interstate commerce.
2026-18307, Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders
FMCSA announces its decision to renew exemptions for five individuals from the requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) that interstate commercial motor vehicle (CMV) drivers have "no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV." The exemptions enable these individuals who have had one or more seizures and are taking anti-seizure medication to continue to operate CMVs in interstate commerce.
Previous / Next Documents
Previous: 2026-18300, Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANDEMBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.
Next: 2026-18302, Certain Glow Fish Tape Systems, Safety Helmet Systems, and Components Thereof; Notice of a Commission Determination To Review in Part a Final Initial Determination Finding a Violation of Section 337; Request for Written Submissions on the Issues Under Review, Remedy, Bond, and the Public Interest
Notice is hereby given that the U.S. International Trade Commission ("the Commission") has determined to review in part a final initial determination ("FID") issued by the presiding chief administrative law judge's ("CALJ") in the above-captioned investigation finding a violation of section 337 of the Tariff Act of 1930, and to solicit briefing on the issues under review as well as remedy, bonding, and the public interest.